

University of Groningen

Making optimal use of available anti-tuberculosis drugs

Alffenaar, J W C; Peloquin, C A; Migliori, G B

Published in:
International Journal of Tuberculosis and Lung Disease

DOI:
[10.5588/ijtld.17.0632](https://doi.org/10.5588/ijtld.17.0632)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Alffenaar, J. W. C., Peloquin, C. A., & Migliori, G. B. (2018). Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. *International Journal of Tuberculosis and Lung Disease*, 22(1), 2-2. <https://doi.org/10.5588/ijtld.17.0632>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone

ACCORDING TO the recently updated World Health Organization (WHO) treatment guidelines for rifampicin-resistant or multidrug-resistant tuberculosis (MDR-TB), an effective treatment regimen consists of at least five effective drugs. The combination consists of a fluoroquinolone (group A), an injectable (group B) and two drugs from group C, in combination with pyrazinamide.¹ Group C consists of ethionamide/prothionamide, cycloserine/terizidone, linezolid and clofazimine. Cycloserine is considered to be the last option in group C due to its limited bactericidal activity and poor tolerability.² Specifically, many patients experience some form of central nervous system disturbance, ranging from tiredness and lethargy to more serious behavioural changes or seizures. The incidence of these various adverse reactions may vary in different populations around the globe, but this has not been well studied. Despite this unfavourable profile, cycloserine is widely used.

Terizidone, a drug consisting of two coupled cycloserine molecules, has been introduced with the aim of increasing tolerability. Due to their introduction on the market more than four decades ago, the development of these drugs lacked modern pharmacokinetics and pharmacodynamic studies to guide the dose selection, and the relation between drug concentration and efficacy and toxicity is therefore poorly understood. As the pharmaceutical industry is not interested in spending resources on the optimisation of these old drugs, research is dependent on public funding.

The first step in the dose optimisation of a drug is often to study its pharmacokinetics in clinical practice. In this issue of the *Journal*, Court and his team studied the pharmacokinetics of 250–750 mg terizidone daily as part of standard treatment regimens for pulmonary MDR-TB in 35 patients in Cape Town, South Africa.³ They collected blood samples over a period of 10 h and analysed the samples using mass spectrometry. An important finding was the long half-life of the drug, which enabled a once-daily dosing strategy. Unfortunately, the design of the sampling scheme and the small sample size did not allow an in-depth covariate analysis to find factors that determined the pharmacokinetics. Although this study did not provide final answers, it is an important first step in the dose optimisation of cycloserine/terizidone. This is com-

parable with another group C drug, linezolid, being evaluated in MDR-TB patients.⁴ The current study will hopefully encourage investigators to initiate more operational research in the quest for the optimal dose of cycloserine/terizidone to find the balance between efficacy and toxicity. Considering the variability in cycloserine drug concentrations at the same dose, therapeutic drug monitoring may find its use in further tailoring the dose in patients who experience treatment response or side effects.^{5,6}

J. W. C. ALFFENAAR*

C. A. PELOQUIN†

G. B. MIGLIORI‡

**Department of Clinical Pharmacy and Pharmacology
University Medical Center Groningen,
University of Groningen
Groningen, The Netherlands*

†*College of Pharmacy and Emerging Pathogens
Institute*

*University of Florida
Gainesville, Florida, USA*

‡*Maugeri Care and Research Institute
Tradate, Italy*

e-mail: j.w.c.alfenaar@umcg.nl

Conflicts of interest: none declared.

References

- 1 Falzon D, Schönemann H J, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. *Eur Respir J* 2017; 49(3): 1602308.
- 2 Caminero J A, Piubello A, Scardigli A, Migliori G B. Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. *Eur Respir J* 2017; 50(1): 1700648.
- 3 Court R, Wiesner L, Stewart A, et al. Steady-state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2017; 21: 30–33.
- 4 Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori G B. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. *Eur Respir J* 2013; 42: 288–290.
- 5 Alffenaar J W C. Therapeutic drug monitoring in tuberculosis: practical application for physicians. *Clin Infect Dis* 2017; 64: 104–105.
- 6 Alsultan A, Peloquin C. Therapeutic drug monitoring in the treatment of tuberculosis: an update. *Drugs* 2014; 74: 839–854.